Roth Capital Reiterates Neutral on Capricor Therapeutics, Raises Price Target to $10.5
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Neutral and raises the price target from $7 to $10.5.
Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Neutral and raises the price target from $7 to $10.5.